[Hepatitis B virus reactivation after cessation of prophylaxis with lamivudine in a patient with non-Hodgkins lymphoma treated with chemotherapy and rituximab].
Vives
Susana
S
Sancho
Juan Manuel
JM
Planas
Ramón
R
Ribera
Josep Maria
JM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006511:Hepatitis B Antigens / Q000097:blood; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000821:virology; D008875:Middle Aged; D012008:Recurrence; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000069283:Rituximab; D014775:Virus Activation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006511:Hepatitis B Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D000069283:Rituximab